The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence

This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analyses, and mechanistic research. A comprehensive literature search across major scientific databases identified empirical studies evaluating psilocybin’s effects on depressive symptomatology, safety, and underlying neurobiological mechanisms. Psilocybin’s primary pharmacological action as a 5-HT2A receptor agonist leads to alterations in brain connectivity, particularly within networks associated with self-referential processing and emotional regulation. These receptor-level effects are accompanied by neuroplastic changes, including enhanced synaptogenesis and functional reorganization, which contribute to the rapid and sustained antidepressant outcomes observed in clinical settings. Neuroimaging studies further support these mechanisms by demonstrating reductions in amygdala activity and modifications within default mode and executive networks following administration. Clinical evidence consistently indicates that psilocybin produces substantial reductions in depressive symptoms, with meta-analyses reporting large effect sizes and durable benefits lasting from several weeks to as long as one year. Randomized controlled trials highlight its rapid onset of action, with remission rates notably higher than those achieved with conventional treatments, including in populations with treatment-resistant depression. Open-label studies reinforce the durability of these effects and emphasize the essential role of psychotherapeutic support in optimizing therapeutic outcomes. Across studies, psilocybin demonstrates a favorable safety profile, with adverse events being mild, transient, and predictable. Despite these promising findings, methodological limitations such as small sample sizes, high heterogeneity, and variability in treatment protocols underscore the need for larger, standardized Phase III trials. Future research should also include direct comparisons with established antidepressants and efforts to identify biomarkers that may guide personalized treatment approaches.